{
  "id": 13145111,
  "title": "Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.",
  "url": "https://urgent.news/2026/10/09/citi-sees-60-upside-in-crispr-therapeutics-heres-what-has-to-go-right-13145111",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T14:00:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/09/citi-sees-60-upside-in-crispr-therapeutics-heres/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "Most of any gains (or lack thereof) from here will be driven by just three factors.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.",
        "url": "https://urgent.news/2026/10/09/citi-sees-60-upside-in-crispr-therapeutics-heres-what-has-to-go-right",
        "published": "2026-10-09T14:20:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}